Lymphatic vascular morphogenesis in development, physiology, and disease

Stefan Schulte-Merker,1,2,3 Amélie Sabine,4,5,6 and Tatiana V. Petrova4,5,6

1Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, and University Medical Centre, 3584 CT Utrecht, Netherlands
2Centre for Biomedical Genetics, 3584 CT Utrecht, Netherlands
3Experimental Zoology Group, Department of Animal Sciences, Wageningen University, 6709 PG Wageningen, Netherlands
4Division of Experimental Oncology, Multidisciplinary Oncology Center, 5Central University Hospital, and 6Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland

The lymphatic vascular system serves key physiological functions: it maintains fluid homeostasis by absorbing water and macromolecules from the interstitium, enables uptake of dietary lipids and vitamins in the intestine, and serves as a trafficking route for immune cells. The lymphatic vasculature consists of a highly branched network of capillaries and ducts that present in most organs with the exception of the central nervous system and avascular tissues, such as cartilage. Unlike the blood vasculature, the lymphatic vasculature is blind ending (Fig. 1 A): its small capillaries funnel first into precollecting and larger collecting vessels and then into the thoracic duct or the right lymphatic trunk, which drains lymph into the subclavian veins.

Introduction

The lymphatic vascular system serves key physiological functions: it maintains fluid homeostasis by absorbing water and macromolecules from the interstitium, enables uptake of dietary lipids and vitamins in the intestine, and serves as a trafficking route for immune cells. The lymphatic vasculature consists of a highly branched network of capillaries and ducts that present in most organs with the exception of the central nervous system and avascular tissues, such as cartilage. Unlike the blood vasculature, the lymphatic vasculature is blind ending (Fig. 1 A): its small capillaries funnel first into precollecting and larger collecting vessels and then into the thoracic duct or the right lymphatic trunk, which drains lymph into the subclavian veins.

Malfunctioning of the lymphatic vasculature results in lymphedema formation and compromises immune function. In the past decade, tremendous progress has been achieved in understanding the mechanisms regulating the morphogenesis of lymphatic vasculature, mainly accomplished by genetically modified mouse models and discovery of mutations responsible for human lymphedema syndromes. In addition, models, such as zebrafish and frog tadpoles, are emerging as powerful tools for studying lymphatic vascular development. In this review, we will summarize the main mechanisms underlying the development of lymphatic vasculature and present an overview of several human diseases that are associated with lymphatic vessel abnormalities.

Mechanisms of lymph transport

The structure of the different lymphatic vascular compartments, such as capillaries, precollecting, and collecting lymphatic vessels, reflects its dual role in fluid absorption and lymph transport. We will briefly present the main aspects of lymph transport, which have been documented in more detail in recent reviews (Dejana et al., 2009; Zawieja, 2009).

Fluid and cell uptake by lymphatic capillaries.

Lymphatic capillary endothelium has a unique junctional organization (Baluk et al., 2007; Dejana et al., 2009). Oak leaf–shaped endothelial cells are connected by discontinuous buttonlike junctions. Free overlapping cell edges anchored on each side by these junctions form “flap valves” (Fig. 1, B and C) through which fluid flows unidirectionally along pressure gradients from the interstitium into the capillary lumen. Actively sprouting lymphatic capillaries have continuous cell–cell junctions, suggesting buttonlike junctions as characteristics of quiescent and functional lymphatic capillary endothelium (Baluk et al., 2007). Lymphatic capillaries lack mural cells and connect to the ECM via anchoring filaments (Leak and Burke, 1968), which prevent the collapse of capillaries upon the increase of interstitial pressure (Fig. 1 B).

Correspondence to Tatiana V. Petrova: tatiana.petrova@unil.ch

Abbreviations used in this paper: BEC, blood endothelial cell; FN, fibronectin; GD, Gorham disease; HHT, hereditary hemorrhagic telangiectasia; KS, Kaposi sarcoma; KSHV, KS-associated herpes virus; LAM, lymphangioleiomyomatosis; LEC, lymphatic endothelial cell; LD, lymphedema-distichiasis syndrome; mTOR, mammalian target of rapamycin; NFAT, nuclear factor of activated T cells; PI, phosphoinositide; SMC, smooth muscle cell; Syk, spleen tyrosine kinase.
Transport of lymph by collecting vessels. Lymph from lymphatic capillaries is first drained into the precollecting lymphatic vessels that have both lymphatic capillary (oak leaf–shaped lymphatic endothelial cells [LECs]) and collecting lymphatic vessel characteristics (valves). Collecting lymphatic vessels consist of a series of functional units, called lymphangions, separated by intraluminal valves, which ensure unidirectional lymph flow (Fig. 1 D). Collecting vessels are covered with a continuous basement membrane and smooth muscle cells (SMCs). Endothelial cells in collecting vessels are elongated and connected by continuous zipperlike junctions (Fig. 1 C). Continuous junctions and basement membrane prevent leakage of lymph during its transport.
Mechanisms of lymphatic vascular development

- Schulte-Merker et al.

Lymph hearts located at the junctions of the lymphatic and venous systems control lymph flow (Kampmeier, 1969).

Lymphatic vascular morphogenesis

Lymphatic vascular development requires transdifferentiation of venous endothelial cells toward the lymphatic endothelial phenotype, separation of blood and lymphatic vasculature, sprouting of lymphatic vessels, and lymphatic vascular maturation (Fig. 2A).

Over 20 genes orchestrate these processes in mice (Table I), and recently, lymphangiogenesis has also been examined in lower vertebrates, such as fish and frogs.

Establishment of LEC identity and lymphatic sprouting

Lymphatic valves contain two semilunar leaflets, which are covered on both sides by a specialized endothelium anchored to the ECM core (Lauweryns and Boussauw, 1973).

High lymph pressure upstream of a valve opens the valve and enables lymph flow, whereas reverse flow pushes the leaflets against each other and closes the valve (Fig. 1D). Therefore, opening and closing of the valve depend on periodic changes in fluid pressure within collecting vessels. The number of valves per vessel segment varies depending on tissue type, being generally highest in organs with high hydrostatic pressure, e.g., legs in humans (Földi et al., 2006).

Cyclical compression and expansion of lymphatic vessels by surrounding tissues and intrinsic pump forces generated by the spontaneous phasic contraction of SMCs regulate lymph propulsion (Zawieja, 2009). The origin of lymphatic SMCs is unknown, but they contain both smooth and striated muscle contractile proteins and, thus, differ from arteriole SMCs (Muthuchamy et al., 2003). Nitric oxide, hormones, and prostanoids control SMC contractions (Zawieja, 2009). In amphibians and reptiles, specialized pulsatile muscular organs or lymph hearts located at the junctions of the lymphatic and venous systems control lymph flow (Kampmeier, 1969).

Figure 2. Main steps of mammalian lymphatic vascular development. (A) LECs are specified in embryonic veins, from where they sprout toward Vegf-c–producing mesodermal cells and aggregate to form lymph sacs. Further sprouting produces the lymphatic primary plexus composed of capillary-like vessels. Myeloid cells produce cytokines and regulate lymphatic vascular morphogenesis. Primary plexus is further remodeled to form collecting, precollecting, and capillary compartments. Precollecting and collecting lymphatic vessels have intraluminal valves and basement membrane coverage. Collecting lymphatic vessels are surrounded by SMCs (red). (Box) Genes important for collecting lymphatic vessel development. (B) IVME-1 is the earliest known LEC marker. The transcription factor Prox1 is essential for the establishment of LEC identity, and its expression is controlled by Sox18. (C) Signaling via Vegfc and Vegfr-3 regulates LEC sprouting and proliferation. The role of Vegfr-2–Vegfr-3 heterodimers and participation of Nrp2 in the Vegfr-2–Vegfr-3 complex are not fully understood. (D) Separation of lymphatic and blood vasculature requires platelet aggregation (also see Table I). Interaction of podoplanin on LECs and CLEC-2 on platelets triggers the Syk, Slp76, and PLC-γ2–dependent signaling cascade leading to platelet aggregation. O-glycosylation by T-Synthase is important for podoplanin function.
Table I. Knockout or mutant mouse models and their phenotypes according to stages of lymphatic vascular morphogenesis

| Gene symbol | Function | Lymphatic vascular phenotype | Expression pattern |
|-------------|----------|------------------------------|--------------------|
| LEC differentiation | | | |
| Prox1 | Transcription factor | No LECs (−/−), chylous ascites (+/−); loss of LEC identity, chylous ascites, obesity [Prox1+/−; Tie2-Cre; Wigle et al., 1999; Harvey et al., 2005; Johnson et al., 2008] | LECs, hepatocytes, lens fiber cells, pancreatic, lung, and intestinal endocrine cells, skeletal muscle, cardiomyocytes |
| Sox18 | Transcription factor | No LECs (−/−, on C57BL/6j background); abnormal patterning (+/−); edema and chylous ascites [heterozygous ragged mutants; Pennisi et al., 2000; François et al., 2008] | Endothelial cells |
| Coup-TfII (NR2F2) | Transcription factor | No LECs (−/−, deletion at or before E9.5); edema, loss of LEC identity, and sprouting (−/−, deletion at later stages; Lin et al., 2010; Srinivasan et al., 2010) | Endothelial cells and SMCs |
| Lymphangiogenesis | | | |
| Vegf-c–Vegfr-3 pathway | | | |
| Vegfr3 | Receptor tyrosine kinase | Hypoplasia, chylous ascites (+/Chy, ENU-induced mutation, loss of tyrosine kinase activity; Karkkainen et al., 2001); lymph sacs formed and defective sprouting (homozygous deletion of ligand-binding domain; Zhang et al., 2010) | LECs, fenestrated blood vascular endothelial cells, blood vascular endothelial cells in tumors and during early embryogenesis |
| Vegfc | Growth factor, ligand for Vegfr-3 | No sprouting of LECs from veins (−/−); hypoplasia, chylous ascites (+/−; Karkkainen et al., 2003) | Macrophages, SMCs, and subpopulation of mesenchymal cells during development |
| Nrp2 | Coreceptor of Vegfr-3 and semaphorins | Transient capillary hypoplasia, defective sprouting (−/−; Yuan et al., 2002; Xu et al., 2010) | Venous and lymphatic endothelial cells |
| Rac1 | Rho GTPase | Abnormal migration of LECs from veins (Rac1+/−; Tie1-Cre; D’Amico et al., 2009) | Broad |
| Clp24 | Transmembrane protein | Lymphangiectasia, ectopic mural cells (Clp24+/−; Clp24+/−; Vegfr3+/−; and Clp24−/−; Vegfr3+/−; Saharinen et al., 2010) | Endothelial cells |
| Tbx1 | Transcription factor | Hypoplasia and chylous ascites (Tbx1+/−; Tie2-Cre; Chen et al., 2010) | Vascular, including LECs |
| Ptpn14 (gene trap) | Protein tyrosine phosphatase | Hyperplasia of dermal lymphatic vessels in 14% of mutants, paw or periorbital edema (Au et al., 2010) | Broad, including LECs |
| Adrenomedullin signaling | | | |
| Adrn | (adrenomedullin) | Peptide vasodilator, ligand for Calcrl | Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, Calcr+/−; Tie2-Cre; Fritz-Six et al., 2008) | Adrenal medulla, vascular SMCs and endothelial cells, cardiomyocytes |
| Ramp2 | Coreceptor of Calcrl | Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, Calcr+/−; Tie2-Cre; Fritz-Six et al., 2008) | Broad, including LECs |
| Calcr (calcitonin receptor-like) | G protein–coupled receptor of adrenomedullin | Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, Calcr+/−; Tie2-Cre; Fritz-Six et al., 2008) | Broad, including LECs |
| Other | | | |
| Vezf | Transcription factor | Transient jugular lymphatic hypervascularization (+/−; Kuhnert et al., 2005) | Broad |
| Tie1 | Receptor tyrosine kinase | Abnormal lymphatic patterning, dilated and disorganized lymphatic vessels (hypermorphic mice on outbred background; D’Amico et al., 2010) | Endothelial and hematopoietic cells |
| Separation of blood and lymphatic vessels | | | |
| Platelet development | | | |
| Meis1 | Transcription factor | Blood-filled lymphatic vessels (−/−; Carramolino et al., 2010) | Broad, including developing hematopoietic cells |
| Platelet aggregation | | | |
| Slp76 | Adaptor protein | Blood-filled lymphatic vessels, chylous ascites (−/−; Abtahian et al., 2003) | Hematopoietic cells |
Table I (continued). Knockout or mutant mouse models and their phenotypes according to stages of lymphatic vascular morphogenesis

| Gene symbol | Function | Lymphatic vascular phenotype | Expression pattern |
|-------------|----------|------------------------------|--------------------|
| Pcg2        | Phospholipase C, hydrolysis of phospholipids | Blood-filled lymphatic vessels, chylous ascites | Broad |
| Pdpn (podoplanin) | Transmembrane glycoprotein | Lymphangiectasia, abnormal lymph transport, lymphedema, blood-filled lymphatic vessels | LECs, keratinocytes, alveolar type II cells, podocytes |
| C1galt1 (encodes T-synthetase) | Glycosyltransferase, biosynthesis of core-1–derived O-glycans | Blood-filled lymphatic vessels, decreased levels of podoplanin | Endothelial and hematopoietic cells |
| Clec-2  | C-type lectin receptor | Blood-filled lymphatic vessels | Platelets, peripheral blood neutrophils |
| Syk        | Nonreceptor tyrosine kinase | Blood-filled lymphatic vessels, chylous ascites, accumulation of myeloid cells in the dermis | |
| Spred1/Spred2 | Cytoplasmic adaptor proteins | Blood-filled lymphatic vessels | Broad, including LECs |

Remodeling, maturation, and valve morphogenesis

| Gene symbol | Function | Lymphatic vascular phenotype | Expression pattern |
|-------------|----------|------------------------------|--------------------|
| Tie/Pi3-kinase signaling | | | |
| Akt1 | Ser/Thr kinase | Capillary hypoplasia, valve agenesis, dilation, and decreased SMC coverage of small collecting lymphatic vessels | Broad |
| Angpt2 | Growth factor, ligand of Tie receptor tyrosine kinases | Hypoaplasia, chylous ascites, defective remodeling, and valve agenesis | (Lymph) angioigenic endothelial cells, hematopoietic cells |
| Pim3ka (mutation blocking interaction with Ras) | Catalytic p110α isoform of PI3-kinase | Chylous ascites, hypoplasia, impaired sprouting, and branching of lymphatic capillaries | Broad |
| Pik3r1 | Regulatory subunits of class IA PI3-kinases | Chylous ascites, intestinal lymphangiectasia, impaired sprouting, lymphatic, valve agenesis | Broad |

ECM assembly and interactions

| Gene symbol | Function | Lymphatic vascular phenotype | Expression pattern |
|-------------|----------|------------------------------|--------------------|
| Itga9 | Adhesion | Chyllothorax, lymphatic valve agenesis | BECs and LECs (highest in valves), vascular SMCs |
| Fn1 | ECM component, ligand of Itga9 | Failure of lymphatic valve leaflet elongation | Broad, including lymphatic valves |
| Emilin1 | Elastic microfibril-associated protein | Hyperplasia and abnormal patterning of lymphatic vessels, reduction of anchoring filaments, impaired lymph drainage, increased lymph leakage | Broad, including LECs |
| Aspp1 | Cytoplasmic adaptor protein | Impaired assembly of lymphatic vessels and collecting lymphatic vessel patterning, accumulation of lymphatic islands | Endothelial cells |
| Ephb2 (mutation of PDZ binding site) | Ligand of EphB receptor tyrosine kinases | Impaired sprouting of capillaries, agenesis of lymphatic valves, ectopic mural cells, chylotothorax, retrograde lymph flow | Arterial endothelial cells and SMCs, LECs (highest in the valves) |
| Foxc2 | Transcription factor | Impaired patterning of capillaries, no collecting lymphatic vessels, agenesis of lymphatic valves, ectopic mural cells, retrograde lymph flow | Arterial endothelial cells and SMCs, LECs (highest in the valves) |
| Elk3 (Net) | Transcription factor | Lymphangiectasia, chylotothorax | Endothelial cells |
| PU.1 | Transcription factor receptor for M-CSF1 | Hyperplasia and abnormal patterning of dermal lymphatic vessels | Hematopoietic cells (stage dependent) |

ENU, Nethyl-N-nitrosourea; PAC, P1-derived artificial chromosome.
In mice, LECs are first specified in the anterior cardinal vein around embryonic day 9.5 (E9.5) when a subset of venous endothelial cells expresses the transcription factor Proxl and the lymphatic vessel hyaluronan receptor-1 (LYVE-1) in a polar manner (Fig. 2 B). Proxl-/- mice do not develop any lymphatic structures because of failed budding and sprouting of LECs (Wigle and Oliver, 1999). The transcription factor Sox18 induces Proxl expression, and Sox18-/- mice develop edema caused by blockage of LEC development in the vein in certain genetic backgrounds (François et al., 2008). In vitro studies demonstrate SOX18 binding to the Proxl/ promoter and show that PROX1 can confer lymphatic identity to blood endothelial cells (BECs; Hong et al., 2002; Petrova et al., 2002; François et al., 2008). Thus, Sox18 and Proxl constitute an essential signaling axis for LEC specification. The nuclear receptor Coup-TFII (Lin et al., 2010; Srinivasan et al., 2010) has an earlier developmental role as a venous identity factor, but it also directly interacts with Proxl (Lee et al., 2009; Yamazaki et al., 2009) and regulates the expression of LEC-specific genes, such as neuropilin-2 (Nrp2; Lin et al., 2010).

Proxl/LYVE-1–positive cells bud and migrate dorsolaterally from the central veins. They subsequently form the first bona fide lymphatic structures (jugular lymph sacs) in regions where lymphangiogenic growth factor Vegf-c is provided by the lateral mesoderm (Fig. 2 A; Karkkainen et al., 2003). This process occurs at several positions along the anterior–posterior axis of the early embryo and results in the formation of jugular, medial, and axial lymph sacs, which further give rise to a primary capillary plexus (Sabin, 1902). Vegf-c is critical in the process: Vegfc-/- mice lack all lymphatic vasculature, and even Vegfc-/-/- displays lymphatic hypoplasia (Karkkainen et al., 2003). The sprouting response of LECs to VEGF-C is mediated by the receptor tyrosine kinase VEGFR-3 and its nonsignaling transmembrane co-receptor Nrp2 (Fig. 2 C). Nrp2 is highly expressed in lymphatic capillaries and becomes internalized together with VEGFR-3 upon stimulation of LECs with VEGF-C and VEGF-D (Kärpänen et al., 2006a). Intriguingly, Nrp2 is important for capillary sprouting but dispensable for the formation of lymph sacs (Yuan et al., 2002; Xu et al., 2010). VEGfr-3 is initially expressed also in BECs but becomes mostly restricted to LECs after E10.5. VEGfr-3 signaling depends on interaction with claudinlike protein Clp24 and receptor internalization, a process requiring ephrin-B2 (Saharinen et al., 2010; Wang et al., 2010). Interestingly, the combined deletion of Vegfr-3 ligands Vegfc and Vegfd in mice does not phenocopy the inactivation of Vegfr3, pointing to a ligand-independent Vegfr3 function (Haiko et al., 2008). Budding of LECs from veins requires Vegfr-3 kinase activity, whereas deletion of the Vegfr3 ligand-binding domain does not alter lymph sac formation (Fig. 2, A–C; Zhang et al., 2010). Proteolytically processed VEGF-C also interacts with VEGFR-2, which is expressed by lymphatic endothelium. However, activation of Vegfr-2 alone promotes lymphatic vessel enlargement but not sprouting (Wirzenius et al., 2007). VEGF-C induces formation of VEGFR-2/VEGFR-3 heterodimers at angiogenic tip cells, suggesting that heterodimerization of VEGFR-3 with VEGFR-2 may contribute to lymphangiogenic sprouting (Nilsson et al., 2010). Endothelial-specific loss of Rho GTPase Rac1 leads to an abnormally close association of lymph sacs and cardinal veins, suggesting that it also regulates LEC budding from veins (D’Amico et al., 2009).

Interestingly, postnatal development of lymphatic vessels in organs other than skin is Vegfc/Vegfr-3 independent, and internal lymphatic capillaries regrow in mice with mutated Vegfr3 or upon Vegfr-c depletion (Karkkainen et al., 2001; Mäkinen et al., 2001; Kärpänen et al., 2006b).

In zebrafish, the secreted protein Ccbe1 controls lymphatic sprouting from veins, and its function is conserved, as CCB-E1 mutations cause human syndrome presenting with lymphatic dysplasia (Alders et al., 2009; Hogan et al., 2009a, see Heredity lymphedema syndromes). The venous origin of LECs and conserved function of VEGF-C, VEGFR-3, and CCB-E1 (Karkkainen et al., 2000, 2003; Ny et al., 2005; Küchler et al., 2006; Yaniv et al., 2006; Alders et al., 2009; Hogan et al., 2009a,b) clearly underpin the common origin of the vertebrate lymphatic vasculature. Nevertheless, within this common scheme, there seem to be differences between mammalian and zebrafish LEC behavior: in mice, lymphatic sprouting occurs after veins have formed, whereas zebrafish venous sprouts and lymphatic precursors emerge from the cardinal vein simultaneously (Bussmann et al., 2010). Half of those venous sprouts connect with intersegmental vessels to form veins, whereas other sprouts disconnect from the vein and migrate toward the horizontal myoseptum region, constituting a pool of future LECs. These cells, called parachordal lymphangioblasts, migrate along arteries either dorsally to form intersegmental lymphatic vessels or ventrally to form the thoracic duct (Bussmann et al., 2010; Geudens et al., 2010). At 5 d after fertilization, a functional lymphatic system has been established in the zebrafish trunk capable of taking up substances from the interstitium and of transporting lymph into the venous system (Küchler et al., 2006; Yaniv et al., 2006). Future studies will have to show whether the requirement for arteries in guiding LEC migration is a zebrafish-specific feature or whether this represents a general scheme among vertebrates: the anatomical proximity of mammalian arteries and lymphatic vessels has often been noted but commonly attributed to high arterial pressure and a need of absorbing extravasated water and proteins near arteries. Using zebrafish, a role for Notch/Dll4 signaling has been demonstrated in guiding LECs along arteries (Geudens et al., 2010), and there might be earlier roles for Notch at the level of venous sprouting (Liao et al., 2010). Interestingly, loss of the arterial regulator synclin also compromises the development of zebrafish lymphatics (Hermans et al., 2010).

Hematopoietic cells and lymphatic vascular development. In mammals, lymphatic and blood vasculatures are connected only in a few defined locations where lymph is returned back to blood circulation. Platelets are important for keeping both vascular systems apart (Table I): platelet depletions or defective platelet aggregation leads to abnormal lymphovenous connections and blood-filled lymphatic vessels (Ichise et al., 2009; Bertozzi et al., 2010; Carramolino et al., 2010; Suzuki-Inoue et al., 2010; Uhrin et al., 2010). According to the current model, platelets aggregate at sites of communication between the cardinal vein and lymph sacs and “seal off” lymphatic vessels from the vein (Fig. 2, A and D). Platelet aggregation is initiated by binding of the O-glycosylated mucoprotein podoplanin expressed on LECs to the Clec-2 receptor on platelets (Bertozzi et al., 2010; Uhrin et al., 2010). Clec-2 further induces intracellular signaling...
cascades mediated by spleen tyrosine kinase (Syk), Slp76, and PLC-γ2, which then lead to formation of the blood clot that seals off the vein from the lymph sac (Ichise et al., 2009; Bertozzi et al., 2010; Suzuki-Imoue et al., 2010).

In addition to platelets, myeloid cells regulate lymphatic vascular morphogenesis. Macrophage-deficient PU.1−/− and Csf1r−/− mice exhibit hyperplastic dermal lymphatic capillaries, suggesting that macrophages restrict proliferation of LECs (Gordon et al., 2010). Conversely, abnormal accumulation of myeloid cells, producing high levels of cytokines and VEGF-D, induces the formation of dermal lymphaticovenous shunts in Syk−/− mice (Böhmer et al., 2010). Similar mechanisms are likely at play in Angptl4−/− mice, in which excessive macrophage activation by chylocromics may be responsible for fusion of intestinal blood and lymphatic vessels (Bückhedin et al., 2007; Lichtenstein et al., 2010).

**Lymphatic vascular remodeling and maturation.**

Starting from E15.5, the lymphatic vasculature is reorganized into lymphatic capillaries, precollectors, and collecting lymphatic vessels (Fig. 2 A). In mice, transient up-regulation of the forkhead transcription factor Foxc2 is the first sign of formation of collecting lymphatic vessels (Normén et al., 2009). Lymphatic valves continue to express high levels of Foxc2 and Prox1 throughout development and in adults. LECs in any given lymphangion decrease the expression of Prox1, Vegfr-3, LYVE-1, and Ccl21, secrete basement membrane components, and acquire SMC coverage (Mäkinen et al., 2005; Norrmén et al., 2009). In the absence of Foxc2, transition from capillary to collecting lymphatic vessel phenotype and formation of lymphatic valves are arrested (Petrova et al., 2004; Norrmén et al., 2009). FOXC2-bound enhancers in LECs are surrounded by nuclear factor of activated T cells (NFAT) binding sites, and pharmacological inhibition of NFAT activation results in lymphatic patterning defects reminiscent of Foxc2−/− phenotypes (Normén et al., 2009). This suggests that Foxc2 and NFAT pathways cooperate in establishing collecting lymphatic vessels.

Ephrin–Eph signaling is essential for embryonic angiogenesis, and targeted inactivation in mice of ephrin-B2 or its receptor EphB4 leads to aberrant embryonic blood vessel formation (Adams and Eichmann, 2010). Reverse signaling via PDZ interaction sites of ephrin-B2 is also required for the maturation of collecting lymphatic vessels (Mäkinen et al., 2005). In mice, the presence of a mutation in this PDZ interaction site of ephrin-B2 prevents the formation of valves and leads to persistent LYVE-1 expression in presumptive collecting vessels. These mutant mice also display defective sprouting of lymphatic capillaries, which acquire ectopic SMC coverage (Mäkinen et al., 2005).

Integrin α9 and its ligand fibronectin (FN) containing the EIIIA domain (FN-EIIIA) control later steps of lymphatic valve formation (Bazigou et al., 2009). The integrin α9–β1 complex binds to FN-EIIIA, tenasin, and osteopontin in vitro and regulates the organization of FN-EIIIA microfibrils. Loss of integrin α9 prevents the elongation of valve leaflets, resulting in the formation of ringlike constrictions, which are unable to prevent lymph backflow (Bazigou et al., 2009). Fn-EIIIA−/− mice have a similar phenotype, demonstrating that FN-EIIIA is a physiologically relevant integrin α9 ligand (Bazigou et al., 2009).

The Tie1 and Tie2 endothelial receptor tyrosine kinases are essential for blood vascular remodeling, maturation, and stabilization, and they also control lymphatic vascular development. Mice hypomorph for Tie1 exhibit LEC hyperplasia and abnormal remodeling of lymph sacs, whereas mice deficient in one of the Tie2 ligands, angiopoietin-2, show defective lymphatic vascular remodeling and lack valves (Gale et al., 2002; Delling et al., 2008; D’Amico et al., 2010). Tie2 activation induces phosphoinositide (PI) 3-kinase and Akt signaling in vitro, and consistent with these observations, mutations in several PI3-kinase pathway components or loss of Akt1 leads to lymphatic-remodeling defects (Gupta et al., 2007; Mouta-Bellum et al., 2009; Zhou et al., 2010). Zebrafish tie2−/− undergoes normal lymphangiogenesis. However, redundancy with Tie1 needs to be examined (Gini et al., 2011).

**Pathological lymphatic vascular morphogenesis.**

Given the importance of lymphatic vessels for normal body functions, it is not surprising that defects of the lymphatic vasculature are implicated in a variety of human pathologies. Roles of lymphatic vessels in tumor metastasis and inflammation have been recently covered in several excellent reviews (Sleeman et al., 2009; Tammela and Alitalo, 2010). Here, we will concentrate on the defects of vascular morphogenesis in human lymphedema syndromes and some rare but debilitating diseases in which lymphatic vasculature is suggested to play a central role.

**Hereditary lymphedema syndromes.** Lymphatic vessel dysfunction results in progressive accumulation of protein-rich interstitial fluid and formation of nonpitting localized tissue swelling or lymphedema (Fig. 3). It is a chronic debilitating condition associated with increased local susceptibility to infections and certain cancers, such as angiosarcoma. Lymphedema can be inherited (primary lymphedema) but is more commonly caused by damage incurred by collecting lymphatic vessels or lymph nodes during cancer surgery or radiation therapy (secondary lymphedema). Pathologies of secondary lymphedema have recently been reviewed (Rockson, 2001, 2008; Tammela and Alitalo, 2010).

Hereditary lymphedema is a rare genetic disorder, which can develop in utero, neonatally, or more frequently, years or decades after birth (Fig. 3 and Table II). Missense mutations within the VEGFR-3 tyrosine kinase domain cause Milroy disease, which is characterized by underdeveloped and dysfunctioning cutaneous lymphatic vessels (Karkkainen et al., 2000; Mellor et al., 2010). Recently, mutations in the recessive CCEB1 gene, shown to control lymphatic sprouting in zebrafish (Hogan et al., 2009a), have been identified in a subset of Henneken syndrome patients, who develop limb lymphedema, dilated intestinal lymphatic vessels, mental retardation, and facial anomalies (Alders et al., 2009). Intestinal lymphatic capillaries are also reduced in number and abnormally patterned, suggesting that defective lymphatic capillary function is a cause of the syndrome (Alders et al., 2009).

Loss-of-function mutations in FOXC2 cause lymphedema–distichiasis syndrome (LD), which is characterized by late onset lymphedema and a double row of eyelashes (distichiasis; Fang et al., 2000). Gain-of-function mutations in FOXC2 occur in patients with lymphedema, but the association of these mutations with distichiasis awaits further investigation (van Steensel et al., 2010).
Lymphedema, mutant proteins might exert a dominant-negative effect either on remaining wild-type GJC2 molecules or other connexins. A subset of PTPN14-deficient mice has hyperplastic lymphatic vasculature, and a role for PTPN14 in restricting Vegfr-3 activation has been proposed (Au et al., 2010).

Lymphangioleiomyomatosis (LAM). LAM is a rare lung disease affecting women of childbearing age characterized by the proliferation of smooth muscle-like cells and lymphatic vessels as well as the formation of pulmonary cysts. LAM can also occur in the axial lymphatics and is associated with a benign kidney tumor angiomyolipoma (Seyama et al., 2010). The origin of the SMCs in LAM lesions is unknown, but they respond to estrogen and express multiple chemokine receptors and lymphangiogenic growth factors VEGF-C and VEGF-D, which may explain the highly metastatic behavior of LAM cells and their close association with lymphatic vessels (Pacheco-Rodriguez et al., 2009; Yu et al., 2009). LAM is a benign neoplasm. However, LAM cells frequently disseminate through lymphatic vessels to distant sites, where they may block lymphatic function, causing accumulation of lymph in the chest and abdominal cavity and lymphedema. The cystic destruction of the lung parenchyma over time impairs lung function, which is ultimately only reversible through lung transplantation (Seyama et al., 2010).

The kinase mammalian target of rapamycin (mTOR) plays a central role in integrating growth factor–activated signaling. Its abnormal activation is a likely cause of LAM, as patients with germline mutations of mTOR repressors tuberosis sclerosis-complex 1 and -2 (TSC1 and TSC2) genes develop the disease. Somatic biallelic loss of TSC2 occurs in sporadic LAM cases (Carsillo et al., 2000; Sato et al., 2002). In line with these findings, encouraging results were observed in patients treated with mTOR inhibitors (Glasgow et al., 2010). Given the close association of LAM cells with lymphatic vessels and the lymphatic pattern of dissemination, combining the blockade of mTOR with antilymphangiogenic therapy seems to be a reasonable further step in developing better treatment for this disease.

Gorham disease (GD). GD is a rare disease of unknown etiology characterized by bone resorption and local vascular proliferation. The disease is frequently complicated by systemic dysfunction of lymphatic vessels, such as chylouthorax and chylous ascites (Radhakrishnan and Rockson, 2008). Endothelial cells in the lesions are likely of LEC origin, as they express LEC markers LYVE-1 and podoplanin, and VEGFR-3 is increased in 50% of vessels (Hagendoorn et al., 2006). Nonendothelial cells from GD lesions resemble immature osteoclasts; they secrete cytokines and angiogenic factors, are highly invasive, and may, thus, contribute to disease progression (Colucci et al., 2006). Moreover, GD osteoclast precursors show increased sensitivity to humoral factors, promoting osteoclast formation and bone resorption (Hirayama et al., 2001). Overall, the clinical picture points to an intriguing link between LEC proliferation and activation of osteoclast-mediated bone resorption; however, at present, no candidate genes for GD have been identified.

Kaposi sarcoma (KS): a case of mixed identity. KS is a tumor caused by human herpes virus 8 (HHV8 or
Mechanisms of lymphatic vascular development

Mechanisms of lymphatic vascular development
• Schulte-Merker et al.

production of proangiogenic and inflammatory cytokines, and unrestricted replicative potential (Mesri et al., 2010). Notably, some of these molecules control endothelial cell differentiation in vitro: four KS micro-RNAs target the transcription factor MAF and contribute to reprogramming of the LEC to BEC phenotype, whereas kaposin-B stabilizes PROX1 mRNA, which has a key role in lymphatic endothelial identity (Hansen et al., 2010; Yoo et al., 2010). Overall, these data provide an intriguing example of virus-mediated change of the endothelial cell differentiation program.

Open questions and outlook

Impressive progress has been achieved in the past decade in the field of lymphatic vascular biology, but many questions remain open.

Table II. Main human hereditary lymphedema syndromes

| Name | Inheritance | MIM number | Main manifestations | Mutated gene | Candidate locus |
|------|-------------|------------|---------------------|--------------|----------------|
| Hereditary lymphedema IA | Autosomal dominant with reduced penetrance | 153100 | Congenital lymphedema, chylous ascites caused by hypoplasia of lymphatic vessels | FLT4 (VEGFR-3) | 5q35.3 |
| Hereditary lymphedema IB | Autosomal dominant with reduced penetrance | 611944 | Lymphedema of lower limbs, nature of lymphatic vascular defects is unknown | Unknown | 6q16.2–q22.1 |
| Hereditary lymphedema IC | Autosomal dominant | 613480 | Lymphedema of limbs, age of onset 1–15 yr, nature of lymphatic vascular defects is unknown | GJC2 (connexin47) | 1q41–q42 |
| Hereditary lymphedema II | Unknown | 153200 | Puberty onset lymphedema, nature of lymphatic vascular defects is unknown | Unknown | Unknown |

Syndromes with lymphedema as a consistent feature

Anhidrotic ectodermal dysplasia with immunodeficiency, osteoporosis and lymphedema | X-linked recessive | 300301 | Severe infections, osteoporosis, nature of lymphatic vascular defects is unknown | IKBKG (Nemo) | Xq28 |
| Cholestasis-lymphedema syndrome (Aagenaes syndrome) | Autosomal recessive | 214900 | Severe neonatal cholestasis, neonatal or childhood onset lymphedema caused by hypoplasia of lymphatic vessels | Unknown | 15q1 |
| Hennekam lymphangiectasia-lymphedema syndrome | Autosomal recessive | 235510 | Lymphedema of limbs, intestinal lymphangiectasia, mental retardation, facial anomalies | CCBE1 | 18q21.32 |
| HIT syndrome | Autosomal dominant | 607823 | Alopecia, ectatic blood vessels, lymphedema, nature of lymphatic vascular defects is unknown | SOX18 | 20q13.33 |
| Lymphedema, microcephaly, chorioretinopathy syndrome | Autosomal dominant | 152950 | Congenital microcephaly and lymphedema, nature of lymphatic vascular defects is unknown | Unknown | Unknown |
| Lymphedema-choanal atresia syndrome | Autosomal recessive | 608911 | Blockage of nasal passage (choanal), lymphedema of lower legs at 4–5 yr, nature of lymphatic vascular defects is unknown | PTPN14 | 1q32–q41 |
| Lymphedema–distichiasis syndrome, yellow nail syndrome | Autosomal dominant | 153400/153300 | Late onset leg lymphedema and metaplasia of Meibomian glands (distichiasis), impaired lymphatic drainage caused by incompetent lymphatic valves | FOXC2 | 6q24.3 |
| Persistence of mullerian derivatives with lymphangiectasia and postaxial polydactyly (Urioste syndrome) | Autosomal recessive? | 235255 | Intestinal and pulmonary lymphangiectasia, protein-losing enteropathy, polydactyly, and mullerian duct remnants | Unknown | Unknown |
| Pulmonary congenital lymphangiectasia | Unknown | 265300 | Congenital pulmonary lymphangiectasia, subcutaneous edema, nonimmune hydrops, chylothorax | Unknown | Unknown |

References can be found under the corresponding Online Mendelian Inheritance of Man (MIM) entry.

KS-associated herpes virus [KSHV]). The lesions are composed of spindle-shaped tumor cells, leaky and highly proliferative vessels, extravasated red blood cells, and inflammatory infiltrate (Mesri et al., 2010). KS cells express markers of both blood (CD34 and CXCR4) and LEC lineages (VEGFR-3, LYVE-1, and podoplanin). Interestingly, KSHV infection of BECs shifts the transcriptional profile toward a LEC phenotype, whereas KSHV infection of LECs induces transcriptional reprogramming toward a more BEC-like phenotype (Hong et al., 2004; Wang et al., 2004).

The major latency viral transcripts expressed in KS cells include the latency-associated nuclear antigen, viral cyclin, vFLIP, viral-encoded micro-RNAs, and kaposin-A and -B. These transcripts are important for KHSV-induced cell proliferation, production of proangiogenic and inflammatory cytokines, and unrestricted replicative potential (Mesri et al., 2010). Notably, some of these molecules control endothelial cell differentiation in vitro: four KS micro-RNAs target the transcription factor MAF and contribute to reprogramming of the LEC to BEC phenotype, whereas kaposin-B stabilizes PROX1 mRNA, which has a key role in lymphatic endothelial identity (Hansen et al., 2010; Yoo et al., 2010). Overall, these data provide an intriguing example of virus-mediated change of the endothelial cell differentiation program.

Open questions and outlook

Impressive progress has been achieved in the past decade in the field of lymphatic vascular biology, but many questions remain open.

Table II. Main human hereditary lymphedema syndromes

| Name | Inheritance | MIM number | Main manifestations | Mutated gene | Candidate locus |
|------|-------------|------------|---------------------|--------------|----------------|
| Hereditary lymphedema IA | Autosomal dominant with reduced penetrance | 153100 | Congenital lymphedema, chylous ascites caused by hypoplasia of lymphatic vessels | FLT4 (VEGFR-3) | 5q35.3 |
| Hereditary lymphedema IB | Autosomal dominant with reduced penetrance | 611944 | Lymphedema of lower limbs, nature of lymphatic vascular defects is unknown | Unknown | 6q16.2–q22.1 |
| Hereditary lymphedema IC | Autosomal dominant | 613480 | Lymphedema of limbs, age of onset 1–15 yr, nature of lymphatic vascular defects is unknown | GJC2 (connexin47) | 1q41–q42 |
| Hereditary lymphedema II | Unknown | 153200 | Puberty onset lymphedema, nature of lymphatic vascular defects is unknown | Unknown | Unknown |

Syndromes with lymphedema as a consistent feature

Anhidrotic ectodermal dysplasia with immunodeficiency, osteoporosis and lymphedema | X-linked recessive | 300301 | Severe infections, osteoporosis, nature of lymphatic vascular defects is unknown | IKBKG (Nemo) | Xq28 |
| Cholestasis-lymphedema syndrome (Aagenaes syndrome) | Autosomal recessive | 214900 | Severe neonatal cholestasis, neonatal or childhood onset lymphedema caused by hypoplasia of lymphatic vessels | Unknown | 15q1 |
| Hennekam lymphangiectasia-lymphedema syndrome | Autosomal recessive | 235510 | Lymphedema of limbs, intestinal lymphangiectasia, mental retardation, facial anomalies | CCBE1 | 18q21.32 |
| HIT syndrome | Autosomal dominant | 607823 | Alopecia, ectatic blood vessels, lymphedema, nature of lymphatic vascular defects is unknown | SOX18 | 20q13.33 |
| Lymphedema, microcephaly, chorioretinopathy syndrome | Autosomal dominant | 152950 | Congenital microcephaly and lymphedema, nature of lymphatic vascular defects is unknown | Unknown | Unknown |
| Lymphedema-choanal atresia syndrome | Autosomal recessive | 608911 | Blockage of nasal passage (choanal), lymphedema of lower legs at 4–5 yr, nature of lymphatic vascular defects is unknown | PTPN14 | 1q32–q41 |
| Lymphedema–distichiasis syndrome, yellow nail syndrome | Autosomal dominant | 153400/153300 | Late onset leg lymphedema and metaplasia of Meibomian glands (distichiasis), impaired lymphatic drainage caused by incompetent lymphatic valves | FOXC2 | 6q24.3 |
| Persistence of mullerian derivatives with lymphangiectasia and postaxial polydactyly (Urioste syndrome) | Autosomal recessive? | 235255 | Intestinal and pulmonary lymphangiectasia, protein-losing enteropathy, polydactyly, and mullerian duct remnants | Unknown | Unknown |
| Pulmonary congenital lymphangiectasia | Unknown | 265300 | Congenital pulmonary lymphangiectasia, subcutaneous edema, nonimmune hydrops, chylothorax | Unknown | Unknown |

References can be found under the corresponding Online Mendelian Inheritance of Man (MIM) entry.
unresolved. Development of novel imaging techniques and analysis of signaling pathways in situ will certainly provide additional insights into the mechanisms of lymphangiogenesis. Considerable phenotypic plasticity of endothelial cells is now obvious; however, the genetic and epigenetic mechanisms of LEC differentiation are far from being fully understood. Contributions of other cell types in regulating lymphatic development and function need to be addressed under physiological and pathological conditions. Finally, organ- and disease-specific features and responses of lymphatic endothelium have not been studied in detail, although this knowledge may have a critical impact on developing better treatments for human pathologies, including lymphedema, cancer, and inflammation.

We thank Caroline Heckman and Jeremiah Bernier-Latmani for discussions, and we apologize to colleagues whose work could not be cited because of space limitations.

The authors' work is supported by the Swiss National Science Foundation (grant PBB00P3-114898), the Medic, Telethon, and Emma Muschamp Foundations, the National Center of Competence in Research Molecular Oncology, the Oncogenesis, the Swiss Cancer Association, the Association for International Cancer Research, the Royal Netherlands Academy of Arts and Sciences, and the Wageningen University and Research Centre.

Submitted: 15 December 2010
Accepted: 11 April 2011

References

Abtahian, F., A. Guerrero, E. Seboda, M.M. Lu, R. Zhou, A. Moscai, E.E. Myers, B. Huang, D.G. Jackson, V.A. Ferrari, et al. 2003. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science. 299:247–251. doi:10.1126/science.1079477

Adams, R.H., and A. Eichmann. 2010. Axon guidance molecules in vascular patterning. Cold Spring Harb. Perspect. Biol. 2:a001875. doi:10.1101/cshperspect.a001875

Alders, M., B.M. Hogan, E. Gjini, F. Salehi, L. Al-Gazali, E.A. Hennekam, J.C. Brice, G., S. Mansour, R. Bell, J.R. Collin, A.H. Child, A.F. Brady, M. Sarfarazi, K.G. Burnand, S. Jeffery, P. Mortimer, and V.A. Murray. 2002. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J. Med. Genet. 39:478–483. doi:10.1136/jmg.39.7.478

Bussmann, J., F.L. Bos, A. Urasaki, K. Kawakami, H.J. Duckers, and S. Schulte-MMerker. 2010. Arteries provide essential guidance cues for lymphatic endothelial cells in the zebrafish trunk. Development. 137:2653–2657. doi:10.1242/dev.048207

Carramolino, L., J. Puentes, C. García-Andrés, V. Azcoitia, D. Riethammer, and M. Torres. 2010. Platelets play an essential role in regulating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ. Res. 106:1197–1201. doi:10.1161/CIRCRESAHA.110.218073

Carsiello, T., A. Aestrinidis, and E.P. Henske. 2000. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lympho-angioendotheliomatosis. Proc. Natl. Acad. Sci. U.S.A. 97:6085–6090. doi:10.1073/pnas.97.11.6085

Chen, L., A. Mupo, T. Huynh, S. Cioffi, M. Woods, C. Jin, W. McKeelhan, L. Thompson-Snipes, A. Baldini, and E. Illingworth. 2010. Tbx1 regulates Vegfβ and is required for lymphatic vessel development. J. Cell Biol. 189:347–424. doi:10.1083/jcb.200912037

Colucci, S., G. Tarabottelli, L. Primo, A. Viale, C. Roca, D. Valdemiri, M. Genni, M. Pagano, M. Grano, A.M. Pogrel, et al. 2006. Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J. Bone Miner. Res. 21:207–218. doi:10.1359/JBMR.051019

Dagenas, S.L., R.L. Hartough, R.P. Erickson, M.H. Witte, M.G. Butler, and T.W. Glover. 2004. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome. Gene Expr. Patterns. 4:611–619. doi:10.1016/j.modgep.2004.07.004

D’Amico, G., D.T. Jones, E. Nye, K. Sapienza, A.R. Ramjuan, L.E. Reynolds, S.D. Robinson, V. Kostourou, D. Martinez, D. Aubyn, et al. 2009. Regulation of lymphatic-blood vessel separation by endothelial Rac1. Development. 136:4043–4053. doi:10.1242/dev.035014

D’Amico, G., E.A. Korhonen, M. Waltari, P. Saharinen, P. Laakkonen, and K. Alitalo. 2010. Loss of endothelial Tie1 receptor impairs lymphatic vessel development—brief report. Arterioscler. Thromb. Vasc. Biol. 30:207–209. doi:10.1161/ATVBAHA.109.196618

Danussi, C., P. Spessotto, A. Petrucco, B. Wassermann, P. Sabatelli, M. Montesi, R. Doliana, G.M. Bressan, and A. Colombatti. 2008. Emilin1 deficiency causes structural and functional defects of lymphatic vascular. Mol. Cell. Biol. 28:4026–4039. doi:10.1128/MCB.02062-07

Deiana, E., F. Orsenigo, C. Molenidini, P. Baluk, and D.M. McDonald. 2009. Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res. 313:175–27. doi:10.1007/s00441-008-0694-5

Dellinger, M., R. Hunter, M. Bernas, N. Gale, G. Yancopoulos, R. Erickson, and M. Witte. 2008. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev. Biol. 319:309–320. doi:10.1016/j.ydbio.2008.04.022

Fang, J., S.L. Dagenais, R.P. Erickson, M.F. Arlt, M.W. Glynn, J.L. Gorski, L.H. Seaver, and T.W. Glover. 2000. Mutations in FOXC2 (MFH-1), only the latter role is rescued by Angiopoietin-1. Cold Spring Harb. Perspect. Biol. 4:175–186. doi:10.1101/cshperspect.a000184

Ferrille, R.E., C.J. Baty, M.A. Kimak, J.M. Karlsson, E.C. Lawrence, M. Franke-Horvath, R. Doliana, G.M. Bressan, and A. Colombatti. 2008. Emilin1 deficiency causes structural and functional defects of lymphatic vascular. Mol. Cell. Biol. 28:4026–4039. doi:10.1128/MCB.02062-07

Fitz-Six, K.L., W.P. Dunworth, M. Li, and K.M. Caron. 2008. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J. Clin. Invest. 118:49–50. doi:10.1172/JCI33302

Fujita, H., J. Gerhardt, J.M. McDaniel, B. Xia, X. Liu, L. Ivanucci, A. Ny, K. Hermans, R. Silaasi-Mansat, S. McGee, et al. 2008. Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequently a lethal disease in mice. J. Clin. Invest. 118:3752–3757. doi:10.1172/JCI36077

Gale, N.W., G. Thurston, S.F. Hackett, R. Renard, Q. Wang, J. McClain, C. Martin, M. Witte, M.H. Witte, D. Jackson, et al. 2002. Angiopoietin-1 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell. 4:311–423. doi:10.1016/S1092-1613(03)00217-4

Geudens, L., R. Herpers, K. Hermans, I. Segura, C. Ruiz de Almodovar, J. Bussmann, F. De Smet, W. Vanveldele, B.M. Hogan, A. Siekmann, et al. 2010. Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. Arterioscler. Thromb. Vasc. Biol. 30:1695–1702. doi:10.1161/ATVBAHA.110.203034
Mouta-Bellum, C., A. Côté, L. Miceli-Libby, M.L. Mancini, T.V. Petrova, L. Liaw, I. Prudovsky, P.E. Thorpe, N. Miura, L.C. Cantley, et al. 2009. Organ-specific lymphangectasis, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PISK regulatory isoforms pSIIalpha, pSIIbeta, and pSIIIalpha. Dev. Dyn. 238:2670–2679. doi:10.1002/dvdy.22078

Muthuchamy, M., A. Gashew, N. Boswell, N. Dawson, and D. Zawieja. 2003. Molecular and functional analyses of the contractile apparatus in lymphatic muscle. PASEB J. 19:920–922.

Nilsson, I., F. Bahram, X. Li, L. Gualandi, S. Koch, M. Jarvis, O. Söderberg, A. A. Assimosim, I. Kholov, B. Prytzvik, et al. 2010. VEGF receptor 2/3 heterodimers detected in situ by proximity ligation on angiogenic spouts. EMBO J. 29:1377–1388. doi:10.1038/emboj.2010.30

Normén, C., K.I. Ivanov, I. A. Longo, M. Bjerklund, P. I. Hiippalainen, B. Schmid, and V. Alitalo. 2002. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. J. Clin. Invest. 111:1313–1323. doi:10.1172/JCI12791

Saharinen, P., H. Helotera, J. Miettinen, C. Norrmén, G. D’Amico, M. Jeltsch, T. Zawieja, D.C. 2009. Contractile physiology of lymphatics. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R129–R139. doi:10.1152/ajpregu.908829.2008

Penner, L., C. M. Anderson, O. Hino, O. Onoue, J. Yatomi, Y. Tomiyama, Y. Yamazaki, Y. Akiyama, et al. 2007. Dynein 2B is required for efficient lymphatic valve formation. J. Cell Biol. 178:115–130. doi:10.1083/jcb.200608010

Pflicke, H., and M. Sixt. 2009. Prefomed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 206:2925–2935. doi:10.1084/jem.200901739

Rigaud-Gracia, A., J. Hacopan, E. Hackett, and C. Kaelin. 2003. Tuberin inhibits PI3K/Akt signaling by interacting with the TSC1 complex. Cancer Cell. 3:117–128. doi:10.1016/S1535-6108(03)00020-7

Sato, T., K. Seyama, H. Fujii, H. Maruyama, Y. Setoguchi, S. Iwashami, Y. Fukuchi, and O. Hino. 2002. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangiomatosis. J. Hum. Genet. 47:20–28. doi:10.1538/jig.10010001

Saharinen, P., H. Helotera, J. Miettinen, C. Norrmén, G. D’Amico, M. Jeltsch, T. Zawieja, D.C. 2009. Contractile physiology of lymphatics. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R129–R139. doi:10.1152/ajpregu.908829.2008

Sato, T., K. Seyama, H. Fujii, H. Maruyama, Y. Setoguchi, S. Iwashami, Y. Fukuchi, and O. Hino. 2002. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangiomatosis. J. Hum. Genet. 47:20–28. doi:10.1538/jig.10010001

Schacht, U., A. Eichmann. 2002. Abnormal lymphatic vessel development in neurofibromatosis type 1. J. Cell Sci. 115:3997–4005. doi:10.1101/gad.158840.2010

Sato, T., K. Seyama, H. Fujii, H. Maruyama, Y. Setoguchi, S. Iwashami, Y. Fukuchi, and O. Hino. 2002. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangiomatosis. J. Hum. Genet. 47:20–28. doi:10.1538/jig.10010001